Daly Richard J purchased $99K of AQST
Daly Richard J purchased 28,025 shares of Aquestive Therapeutics, Inc. (AQST) at an average of $3.54 ($3.53–$3.54) across 2 trades on 2026-11-10.
How this was made
The 30-second read
Why it matters
Director-level buying, though modest, may be interpreted as confidence in upcoming developments.
Market read
A routine insider purchase with limited material impact; primarily of interest to short‑term traders monitoring insider activity.
What to watch
Potential upcoming clinical data or partnership not disclosed could be the real driver behind the purchase.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Director Daly Richard J bought 28,025 shares for $99,330, increasing his stake to 28,025 shares.
potential modest upside pressure as market prices in insider buying
The purchase is small relative to market cap, but director-level buying is viewed positively by traders.
Market effects
Minimal impact on the biotech sector; only a single insider transaction.
No regional effect; confined to AQST shareholders.
Low global relevance.
Counterpoint
The purchase is too small to affect price; could be routine portfolio rebalancing.
Key entities
- companyAquestive Therapeutics, Inc.
Biopharma company developing treatments for neurological disorders.
- personDaly Richard J
Director of AQST who executed the purchase.


